A $28 Billion Opportunity Most Vendors Are Missing The 505(b)(2) pathway generates billions in annual drug revenue and runs on […]

Pharmaceutical executives routinely talk about patent cliffs as if they were acts of nature. They are not. The shape of

A strategic analysis for pharmaceutical companies, generic manufacturers, investors, and policy professionals The Indian Clock In most patent systems, the

Every major pharmaceutical patent war starts with a single form filed with the FDA. It is not a lawsuit. No

How litigation patterns, settlement timelines, and competitive pressure in biologics are rewriting the industry’s talent map — and what that

The Clock You Are Ignoring Every branded drug in the specialty channel has an expiration date that has nothing to

The Patent Clock Is a Sales Calendar Every drug patent that expires is a starting gun, not a finish line.

There’s a certain genre of drug question that never goes out of style: “Can this thing I’m already taking also

Courts can triple damages for willful infringement. A flawed freedom-to-operate search is not a defense — it is evidence you